Treatment & Prevention
We regularly sponsor clinical trials to test possible new and improved treatments for Alzheimer’s disease (AD). These studies help to determine if new or currently used medications can prevent AD or slow its progression.
The BU ADC was one of six nationwide sites for the NIA-funded prevention study called ADAPT. This large clinical trial examined whether certain medications, known as non-steroidal anti-inflammatory medications (NSAIDs), could prevent AD. Although treatment ended in 2004, we are currently following-up with participants to determine if there were any long term benefits of the treatment.
We also participate in studies sponsored by the national Alzheimer’s Disease Cooperative Study (ADCS). We are one of approximately 75 participating sites in the ADCS, which collectively conduct large-scale studies that would not be possible at any one individual site.